BioSpace News Archive

Merck, known as MSD outside of the United States and Canada, announced that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the UBS BioPharma Conference on Wednesday.

Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced financial results for the third quarter ended September 30, 2023 and provided a general business update.

Clearside Biomedical, Inc. announced the completion of recruitment in its ODYSSEY Phase 2b clinical trial, a randomized, double-masked, parallel-group, active-controlled, multi-center study in participants with neovascular age-related macular degeneration.

Applied Therapeutics, Inc. today announced that it will host a Diabetic Cardiomyopathy (DbCM) expert forum with key opinion leaders on Tuesday, November 7, 2023 at 8:00 a.m. ET.

Celcuity Inc. today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences.

Ginkgo Bioworks today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2023, on Wednesday, November 8, 2023, beginning at 5:30 p.m. ET.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2023 financial results.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company.